Pfizer announced today the new serotypes included in its 20-Valent pneumococcal conjugate vaccine candidate, PF-06482077, being investigated for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes covered in the vaccine in adults aged 18 years and older. Pfizer’s 20vPnC candidate includes the 13 serotypes contained in Prevnar 13 plus 7 additional serotypes. Pfizer also announced that data from a Phase 2, proof-of-concept study of 20vPnC in adults have been accepted for oral presentation at the upcoming 29th European Congress of Clinical Microbiology and Infectious Diseases, which will take place in Amsterdam, Netherlands, from April 13-16, 2019. In addition, three Phase 3 trials have been initiated for the purpose of evaluating 20vPnC in adults. Combined, these three trials will enroll more than 6,000 adult subjects, including populations of vaccine-naive adults and adults with prior pneumococcal vaccination. All seven of the new serotypes included in 20vPnC are global causes of invasive pneumococcal disease, and six of the seven serotypes are associated with high case-fatality rates. In addition, four of these serotypes are associated with antibiotic resistance and/or meningitis. Together, all of the 20 serotypes included in 20vPnC are responsible for the majority of currently circulating pneumococcal disease in adults in the U.S. and globally
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.